Brain Organoid Therapeutics

Screening Platform

Innovating the future of human tissue-based drug screens in neurology and oncology

Brain Organoid Therapeutics (BOT) provides access to high-quality human brain tissue models, neuronal phenotyping, drug screening and machine learning-based analytical capacity for pre-clinical research and translational studies.

The BOT screening platform is set up to collaborate with industry and academic researchers who want to leverage functional human brain models in vitro to expedite therapeutic translational success.

Brain Organoid Therapeutics is a pioneering biotechnology CRO dedicated to advancing neurotherapeutics through state-of-the-art human brain models in vitro. Our team of experts combines cutting-edge research and innovative methodologies to create electrophysiologically relevant organoids that closely mimic human brain tissue. This allows us to study neurological disorders at a physiological level, facilitating the development of targeted treatments for conditions such as adult and pediatric dementia, Parkinson’s disease, brain cancer, and other neurodegenerative illnesses. Our commitment to scientific excellence and patient well-being drives our mission to transform the landscape of brain health.

Collaborate and leverage human brain models in vitro to enable precise therapeutic translation

Our Services

We provide phenotyping and drug screening services based exclusively on high quality human tissue models in vitro. Our platform is equipped with automated state-of-the-art technologies and highly trained professional staff to provide our partners with reproducible, timely and in-depth neuropharmacological insights.

Our phenotypic services include electrophysiology, neurotoxicity, neuroinflammation and disease-specific rescues.

Our team, led by Prof Bardy, has >15 years of experience analysing human brain tissue in vitro.

We collaborate with industry and academic partners and will tailor the scope of work to specific projects.

BOT offers expert laboratory testing and analysis of drug efficacy on live human brain tissue in vitro with high throughput capacity. We provide thorough functional neurotoxicity assays on healthy or patient-derived brain tissue. Our state-of-the-art facilities provide timely and high-quality results for informed decision-making. Our drug screening services are relevant for any drugs penetrating the blood-brain barrier.
We provide iPSC reprogramming services from skin biopsies or blood cells and extensive pluripotency quality checks.
BOT offers therapeutics validation on a rapidly expanding range of patient-derived iPSC neuronal models readily available, including adult and pediatric dementia, Parkinson’s disease, Mucopolysaccharidosis, and motor neuron diseases.
We also have access to >50 patient-derived glioma cell lines (early passages), which are extensively phenotyped and represent the diversity of brain cancer patients.
Our well-characterised disease models in vitro can be used to assess the therapeutic potentials of new compounds without putting patients at risk.
We provide a range of cutting-edge phenotyping assays, including electrophysiology, transcriptomics, high-content imaging, neurotoxicity, neuroimmune responses and metabolic homeostasis. We can also integrate gene-editing, genomics, and functional genomics with our local partners.
We have >20 years experience in electrophysiology, including Patch-clamping, Multielectrode arrays and calcium imaging.
We provide detailed electrophysiological insights on the effects of drugs on human neurophysiology.
We also provide analytical services of electrophysiological data collected externally.
We provide automated laser scanning confocal imaging in up to 384 well plate formats.
We also provide label-free live imaging over extended periods in vitro (incucyte SX5).
We provide project-based solutions using 2D, 3D, organoid or assembloid cultures of human brain cells, including neurons and glia/astrocytes.
We have access to a rapidly expanding library of neuronal cell types, including excitatory glutamatergic neurons, inhibitory GABAergic neurons, and dopaminergic neurons.
We have access to rapidly expanding numbers of protocols to generate brain region-specific tissue, including cortical, midbrain and more.
We are also expanding our capacity in collaboration with partners to provide screening access relevant to the peripheral nervous system, including motor and sensory neurons.
Our team of programmers have expertise in machine learning solutions using python (and R) to analyse electrophysiological data, transcriptomics and imaging data.
We provide analysis solution with data collected internally or externally.
We collaborate with clinical trial platforms at SAHMRI, Flinders and local hospitals to provide patient-derived brain tissue analysis and predict drug responders from non-responders using extensive in vitro biological surrogates.